Search Results - "Mirtti, Tuomas"

Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomy.

Authors: Lintula, Susanna Mirtti, Tuomas Rannikko, Antti et al.

Source: Scandinavian Journal of Clinical & Laboratory Investigation. Oct2019, Vol. 79 Issue 6, p424-430. 7p.

Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI--A Comparison with the General Population.

Authors: Pylväläinen, Juho Hoffström, Jaakko Kenttämies, Anu et al.

Source: Cancer Epidemiology, Biomarkers & Prevention. May2024, Vol. 33 Issue 5, p749-756.

Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression.

Authors: Saarinen, Irena Mirtti, Tuomas Seikkula, Heikki et al.

Source: PLoS ONE. 10/15/2015, Vol. 10 Issue 10, p1-16. 16p.

Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy.

Authors: Lahdensuo, Kanerva Mirtti, Tuomas Petas, Anssi et al.

Source: Scandinavian Journal of Urology (Taylor & Francis Ltd). Apr2015, Vol. 49 Issue 2, p90-96. 7p.

Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre.

Authors: Boström, Peter J. Mirtti, Tuomas Kössi, Jyrki et al.

Source: Scandinavian Journal of Urology & Nephrology. Oct2009, Vol. 43 Issue 5, p357-364. 8p. 1 Diagram, 4 Charts, 1 Graph.

Group IIA phospholipase A2 as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.

Authors: MIRTTI, TUOMAS LAINE, VELI JUKKA O. HIEKKANEN, HEIKKI et al.

Source: APMIS. Mar2009, Vol. 117 Issue 3, p151-161. 11p. 6 Color Photographs, 4 Charts, 2 Graphs.

Standardized Reporting of Core Needle Biopsy Tortuosity: BiopTort--A Computer-Aided Protocol for Categorizing Tortuosity.

Authors: Jacobs, Jackson Wiener, Dan Pathak, Tilak et al.

Source: Archives of Pathology & Laboratory Medicine. Mar2026, Vol. 150 Issue 3, p218-228. 11p.

This result is not displayed to guests.
Login for full access.

OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer.

Authors: Halkola, Anni S. Joki, Kaisa Mirtti, Tuomas et al.

Source: PLoS Computational Biology. 3/10/2023, Vol. 19 Issue 3, p1-30. 30p. 2 Diagrams, 2 Charts, 7 Graphs.

How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?

Authors: Mirtti, Tuomas Aittokallio, Tero Seyednasrollah, Fatemeh et al.

Source: European Urology. Sep2017, Vol. 72 Issue 3, pe68-e71. 4p.

Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

Authors: Haddad, Bassem R. Erickson, Andrew Udhane, Vindhya et al.

Source: Cancer Epidemiology, Biomarkers & Prevention. Oct2019, Vol. 28 Issue 10, p1942-1951.

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.

Authors: Rannikko, Antti Leht, Mare Mirtti, Tuomas et al.

Source: BJU International. Aug2022, Vol. 130 Issue 2, p193-199. 7p.

Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.

Authors: Auvinen, Anssi Tammela, Teuvo L. J. Mirtti, Tuomas et al.

Source: JAMA: Journal of the American Medical Association. 5/7/2024, Vol. 331 Issue 17, p1452-1459. 8p.

Comparable recurrence risk for MRI‐detected Gleason Grade Group (GG) 2 and systematic biopsy‐detected GG1 prostate cancer.

Authors: Batouche, Abderrahim‐Oussama Czeizler, Eugen Lehto, Timo‐Pekka et al.

Source: BJU International. Mar2026, Vol. 137 Issue 3, p547-554. 8p.

Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma.

Authors: Roos-Mattila, Matilda Kallio, Pauliina Luck, Tamara J. et al.

Source: Communications Biology. 10/20/2024, Vol. 7 Issue 1, p1-18. 18p.

Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses.

Authors: Turpin, Rita Peltonen, Karita Rannikko, Jenna H. et al.

Source: OncoImmunology. Dec2025, Vol. 14 Issue 1, p1-12. 12p.

A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.

Authors: Mason, Mike Lapuente-Santana, Óscar Halkola, Anni S. et al.

Source: Journal of Translational Medicine. 4/21/2024, Vol. 22 Issue 1, p1-16. 16p.

Protocol liver biopsy predicts graft survival after liver transplantation.

Authors: Liukkonen, Ville H. Nordin, Arno J. Färkkilä, Martti A. et al.

Source: Clinical Transplantation. Mar2024, Vol. 38 Issue 3, p1-13. 13p.

Low nuclear expression of HIF‐hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence‐free survival in clear cell renal cell carcinoma.

Authors: Luomala, Lassi Mattila, Kalle Vainio, Paula et al.

Source: Cancer Medicine. Feb2024, Vol. 13 Issue 3, p1-15. 15p.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.

Authors: Rautiola, Juhana Lampinen, Anita Mirtti, Tuomas et al.

Source: PLoS ONE. 4/21/2016, Vol. 11 Issue 4, p1-15. 15p.